Health News Releases

  • Today February 19
May 02, 2014 14:45
ElectroCore: Two separate studies on the treatment of migraine headache with non invasive vagus nerve stimulation are being presented at the American Association of Neurology (AAN) meeting in Philadelphia
At the AAN meeting in Philadelphia, two separate studies showed that electroCore’s non invasive vagus nerve stimulation (nVNS) therapy was effective in helping patients with different types of migrain
May 01, 2014 19:00
Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin achieved an overall survival of 6.1 months, a 1.9 month improveme
April 30, 2014 17:35
Boehringer Ingelheim to present highly anticipated Phase III data in IPF and COPD at ATS International Conference
For media outside UK, U.S. and Canada Boehringer Ingelheim announced today that the first results of the two confirmatory Phase III INPULSISTM trials, investigating nintedanib* in the treatment of
April 30, 2014 12:00
Asklepios Accelerates Investments in Equipment, Technology and Quality of Staff: Self-Imposed Claim as an Innovative Former in the Health System Makes Clear That the Safety of Patients and Employees is at the Focus
Asklepios Kliniken GmbH, holding company of the health care Group Asklepios, once again shows sustainable growth at all levels of the company. Asklepios invested in fiscal year 2013 mainly in modernis
VeinViewer Vision2, Christie's latest advancement in vein illumination.
April 28, 2014 21:00
Christie Medical Holdings Unveils Sixth Generation VeinViewer Vision2
Christie Medical Holdings (www.christiemed.com), Inc., the inventor and global leader of direct projection vascular imaging systems, today unveiled VeinViewer® Vision2 (http://goo.gl/ePxAmC). VeinView
April 28, 2014 15:55
Positive CHMP opinion for Pradaxa® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots
For media outside of the U.S., the UK & Canada only Boehringer Ingelheim announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a
April 25, 2014 14:00
Quintiles and Biogen Idec Announce Comprehensive Clinical Development Partnership
Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, and Biogen Idec (NASDAQ: BIIB) have entered into a five-year strategic clinical developmen
April 18, 2014 14:00
Quintiles Recognized as Industry Leader in Phase II/III Research for Second Year in a Row
For the second year in a row, Quintiles has been named the industry leader that best differentiates itself on service quality for Phase II/III research in Industry Standard Research’s (ISR) 2014 (http
April 17, 2014 19:50
Volasertib, Boehringer Ingelheim´s investigational treatment of acute myeloid leukaemia, is granted ‘orphan drug designation’ in the EU and the US
For media outside of the US and UK only Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) and the European Commission have granted volasertib* ‘orphan drug designa
April 17, 2014 15:45
ASCO, ESMO, EORTC, ESO, and UICC Continue Endorsing the WIN Symposium Series in 2014
Five major cancer organizations which have endorsed previous events in the WIN Symposium Series, are also endorsing the WIN 2014 Symposium, to be held in Paris, June 23 - 24. The high scientific level
April 15, 2014 19:20
Irvine Scientific Announces Expansion of BalanCD™ Product Line to Serve Vaccine Market
Irvine Scientific (www.irvinesci.com) is pleased to announce the launch of its BalanCD™ MDCK (http://goo.gl/WBpyez) cell culture medium, a next generation cell culture product responding to today’s re
April 15, 2014 11:25
Real-World Patient Survey Data Shows Negative Impact of Nocturia
New patient survey data presented today at the European Association of Urology (EAU 14) congress, showed that nocturia (waking to void one or more times a night followed by sleep), has a strong negati
April 14, 2014 13:35
New Studies Show Health Risks from Wireless Tech: Warnings from the BioInitiative Working Group
The BioInitiative Working Group says evidence for health risk from wireless tech is growing stronger and warrants immediate action. The Group released a mid-year update covering new science studies fr
April 10, 2014 12:00
Quintiles’ First Quarter 2014 Earnings Call Scheduled for Thursday, May 1st
Quintiles Transnational Holdings Inc. (NYSE: Q) will release its financial results for the first quarter of 2014 prior to its quarterly earnings call on Thursday, May 1, 2014, at 8:00 a.m. EDT. The
April 08, 2014 20:00
CEO Roundtable on Cancer Launches the Project Data Sphere Initiative, A New Data Sharing and Analytic Platform for Cancer Patient Benefit
Project Data Sphere, LLC (PDS), an independent not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium (LSC), announced today the launch of a new data sharing platform (ww
April 08, 2014 18:35
FDA approves Pradaxa® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)
For media outside of the U.S., the UK & Canada only Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate) for the treatm
April 08, 2014 13:40
Sun Pharma to Acquire Ranbaxy in a US$ 4 Billion Landmark Transaction
Sun Pharma and Ranbaxy today announced entering into definitive agreements for Sun Pharma to acquire 100% of Ranbaxy in an all-stock transaction. Under these agreements, Ranbaxy shareholders will rece
April 08, 2014 12:00
Bioventus Releases New EXOGEN® and Performance Guarantee in Canada
Bioventus, a global leader in active orthopaedic healing, today announced that the next generation of its market-leading[1] EXOGEN® Ultrasound Bone Healing System - including new compliance features a
Immunohistochemical analysis of paraffin-embedded human lung carcinoma using PD-L1 (E1L3N) XP® Rabbi
April 06, 2014 23:00
Cell Signaling Technology, Inc. Announces PD-L1 Antibody, Important to Cancer Immunotherapy Research
Cell Signaling Technology, Inc. (CST) of Danvers, MA, announced today that it has introduced a highly specific PD-L1 rabbit monoclonal antibody (mAb). Recent reports have shown PD-L1 to be up-regulate
April 02, 2014 13:45
CROMA-PHARMA announced the signing of a significant Distribution Agreement with Asia´s leading Producer of Botulinum Toxins and Anti-Aging Products
Family owned, Austrian company CROMA-PHARMA announced today the signing of a 10 year comprehensive and important distribution agreement with Hugel Inc. of Korea. Hugel Inc. is the leading producer of
March 28, 2014 13:00
Quintiles Appoints Dr. Stella Blackburn to Lead Global Risk Management for Real-World & Late Phase Research
Quintiles today announced that Stella Blackburn, M.B. B.S., has been appointed as the vice president and global head of Risk Management for its Real-World & Late Phase Research group. In this role, Dr
March 28, 2014 10:00
Nature Genetics Founding Editor Kevin Davies Joins Pathway Genomics’ Scientific Advisory Board
Pathway Genomics Corporation (www.pathway.com), a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced that Nature Genetics founding edi
March 27, 2014 12:00
Quintiles Announces Exercise of the Underwriters’ Option to Purchase Additional Secondary Shares
Quintiles today announced that the underwriters of the previously announced secondary public offering of 15 million shares of its common stock have exercised in full their option to purchase an additi
March 25, 2014 17:00
Otsuka Pharmaceutical‘s Samsca® Approved in Japan as the World’s First Drug Therapy for ADPKD, a Rare Kidney Disease
Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced it has become the first company in the world to obtain regulatory approval for a pharmacological treatment of autosomal dominant polycystic kid
March 25, 2014 15:30
New Pradaxa® data to be presented during the American College of Cardiology’s 63rd Annual Scientific Session
For media outside of the US, the UK & Canada only Boehringer Ingelheim has today announced that new findings from ongoing Pradaxa® (dabigatran etexilate) research will be presented during the Ameri
25 per page50 per page75 per page100 per page